CN1686281A - Traditional Chinese medicine for treating stomach cancer and its preparation technology - Google Patents
Traditional Chinese medicine for treating stomach cancer and its preparation technology Download PDFInfo
- Publication number
- CN1686281A CN1686281A CN 200510038885 CN200510038885A CN1686281A CN 1686281 A CN1686281 A CN 1686281A CN 200510038885 CN200510038885 CN 200510038885 CN 200510038885 A CN200510038885 A CN 200510038885A CN 1686281 A CN1686281 A CN 1686281A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine
- clear paste
- bletillae
- gastric cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine for treating stomach cancer is proportionally prepared from 3 Chinese-medicinal materials including oldenlandia, bletilla tuber, etc. Its preparing process is also disclosed.
Description
Technical field
The invention belongs to field of traditional Chinese medicine pharmacy, particularly a kind of Chinese medicine for the treatment of gastric cancer the invention still further relates to the preparation technology of this medicine.
Background technology
Gastric cancer is one of human common malignancy, and sickness rate accounts for half of digestive tract tumor, belongs to categories such as the traditional Chinese medical science " dysphagic ", " regurgitation ", " lump in the abdomen ", " gathering ", " fullness in the epigastrium especially referring to the abcess of the abdomen in ancient times ", " gastric abscess ".
The main means of current treatment tumor are chemotherapy, radiotherapy, operative treatment, but chemotherapy, radiotherapy are in killing tumor cell, normal cell is also had great destruction, and these therapies make the hemopoietic system of human body and immunologic function be subjected to grievous injury, very easily cause patient death.
In recent years, screen antitumor drug the Chinese herbal medicine that people begin is little from toxic and side effects, effect is unique, the plant, especially to heat and toxic materials clearing away medicine, drug for invigorating blood circulation and eliminating stasis, set upright tonic and have research that considerable progress is arranged.Heat and toxic materials clearing away medicine can be controlled the development of inflammation and tumor around the tumor to a certain extent, and there is certain curative effect in certain stage of some malignant tumor or some malignant tumor.Ancient medicine is called malignant tumor " malignant boil ", because of disease see burst difficultly receive, be magic flower outward, skin and flesh is rotten black, the smelly dirty name of pus and blood.Golden Mirror of Medicine is pointed out when the pathogeny of narration carbuncle malignant boil: " all poisonous gas-tight plug meridians, battalion defends stops up the event that stagnates." illustrated that evil poison is the principal element that causes malignant changes such as tumor.At present, relatively more rare on market based on the Chinese medicine of the treatment gastric cancer of heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling.
Summary of the invention
The Chinese medicine that the purpose of this invention is to provide the low treatment gastric cancer of a kind of good effect, side effect.
Another object of the present invention provides the preparation technology of above-mentioned Chinese medicine.
Technical scheme of the present invention is the theory according to motherland's medical science, selects for use corresponding Chinese prescription to form.Motherland's medical science is thought, stomach receiving food and drink, digesting food, with reduce to and, happiness profit and dislike dry.If diet is improper, hungry full imbalance, taste are deficient, stay in the phlegm-damp and cause, and the pent-up heat-transformation is burnt in the pyretic toxicity, for the stasis of blood becomes knot, so bright Xu Chun garden ancient and Modern Medicine is pointed out " QI and blood day loses, and fire is gradually vehement mutually, and how much are unlikely dysphagic "; Or feelings will is not smooth, depression of liver-QI, and Yu Huahuo of a specified duration, blood stasis dispelling becomes expectorant, the internal resistance of the expectorant stasis of blood, pyretic toxicity pents up, and with the passing of time becomes painful abdominal mass, in bulk, stops gastral cavilty, thus " caking person, blood that must be tangible is also " (clear Wang Qingren), " food must not descend the person, depressed unable to walk " (bright Zhang Jingyue).This shows that pyretic toxicity pents up, the internal resistance of the expectorant stasis of blood is the main etiology and pathogenesis of gastric cancer, thus Golden Mirror of Medicine day " three positive accumulation of heats; meaning stomach, small intestinal, large intestine, three mansion accumulation of heats do not loose, refining body fluid burns ... cardia is withered; it is narrow then to include the road of frying paddy in, thus food can not descend, for dysphagia also; Pylorus is withered, and the road of then emitting corruption is narrow, thus instead going out of eating, for regurgitation of food from the stomach also ".
The spleen and stomach provide the material basis of the acquired, source of generating QI and blood, and the internal resistance of the expectorant stasis of blood, pyretic toxicity pents up with the passing of time then that QI and blood is two loses, thus first Zhu Dan small stream " danxi's experiential therapy " cloud, " regurgitation, nearly four: blood deficiency, the deficiency of vital energy, heat is arranged, expectorant is arranged ".In a word, gastric cancer is this with the dysfunction of spleen and stomach, and expectorant is turbid, blood stasis, pyretic toxicity is detained is mark, belongs to deficiency in origin and excess in superficiality.Right gastric cancer it " lump in the abdomen ", " gathering " are typical fullness in the epigastrium and abdomen disease.The spleen is in charge of sending up essential substances, and stomach is advocated peace and fallen, the fullness in the epigastrium and abdomen stagnating in middle-JIAO, make the part of the body cavity above the diaphragm housing the heart and lungs do not have give birth to, the part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels does not have institute and falls, the three warmers QI-blood circulation is contrary disorderly, real be anxious critical time." 30 pieces of symposiums on medical topics " thinks " disease indicate this, overlook either of the two, and when critical, then must control its mark earlier ".The internal resistance of the expectorant stasis of blood, pyretic toxicity pents up in gastral cavilty, can make the scorching hot pain of gastral cavilty, localized pain and tenderness, epigastric oppression piece distension, heating, xerostomia is bitter or see hematemesis, and big dry stool is black, purplish tongue, thready and hesitant pulse or string.So the expectorant stasis of blood internal resistance of gastric cancer, pyretic toxicity pents up card, controls suitable heat-clearing and toxic substances removing, activating blood and eliminatng dampness, reducing swelling and alleviating pain.
The present invention selects for use Herba Hedyotidis Diffusae, the Pseudobulbus Bletillae (Rhizoma Bletillae), Herba Solani Lyrati prescription to form, and wherein Herba Hedyotidis Diffusae is cold in nature, and mildly bitter flavor, sweet is directly gone into stomach, large intestine, small intestinal three YANG meridians, the special heat-clearing and toxic substances removing of merit, and activating blood and eliminatng dampness, reducing swelling and alleviating pain are monarch; Herba Solani Lyrati is cold in nature, and sweet in the mouth is gone into Liver Channel, can clean detoxifcation, activating blood and eliminatng dampness, and pain relieving is a minister, and the two mutual reinforcement between is share, and walks and does not keep, and adjustable liver stomach function regulating strengthens heat-clearing and toxin-vanquishing, eliminates the phlegm except that the stasis of blood merit of dissipating depression of QI eliminating stagnation; The Pseudobulbus Bletillae (Rhizoma Bletillae), cold nature, bitter in the mouth, sweet, puckery is returned liver, stomach warp, keeps and does not walk, can detumescence and promoting granulation, hemostasis is told in the town, can prevent invigorating blood circulation too, and evil poison scatters and is using corrigent.Three medicines and usefulness, though the property of medicine is cold, flavor is bitter partially, the flat matter of property and, reside that it is sweet to suffer from, unlikely wound just; Merit is specially invigorated blood circulation, but the not forcing blood of invigorating blood circulation, the stasis of blood is not stayed in hemostasis; The effectiveness detoxifcation so relieves internal heat and does not forget to hold back poison, can draw anxious critical time, the merit of playing heat-clearing and toxic substances removing, activating blood and eliminatng dampness, reducing swelling and alleviating pain, anticancer stomach function regulating altogether.
The objective of the invention is to realize by following measures:
A kind of Chinese medicine for the treatment of gastric cancer is characterized in that it is formulated by following bulk drugs:
Herba Hedyotidis Diffusae 2-16 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 2-16 part, Herba Solani Lyrati 1-8 part.
The Chinese medicine of described treatment gastric cancer, its dosage form are the dosage form that allows on any pharmaceutics.
The Chinese medicine of described treatment gastric cancer, its medicament are pill, tablet, powder, granule, capsule, drop pill, syrup, medicated wine, oral solutions, injection.
The preparation technology of the Chinese medicine of described treatment gastric cancer, its step is as follows:
A. get the Pseudobulbus Bletillae (Rhizoma Bletillae) by above-mentioned prescription and adopt superfine communication technique to be ground into micropowder, standby;
B. get Herba Hedyotidis Diffusae and Herba Solani Lyrati, 6-10 times of 70-95% alcohol reflux 2-3 time, each 1-3 hour, backflow left standstill, and filtered, and reclaimed ethanol, filtrate concentrates, clear paste I; Medicinal residues boil 2-3 time with 6-10 times of decocting, each 1-3 hour, discard medicinal residues, get that decoction liquor leaves standstill, filtration, filtrate concentrate, clear paste II;
C. Pseudobulbus Bletillae (Rhizoma Bletillae) micropowder, clear paste I, clear paste II are mixed, technology adds suitable adjuvant and makes required dosage form routinely.
Described preparation technology, the wherein average diameter of Pseudobulbus Bletillae (Rhizoma Bletillae) micropowder≤20 μ m.
Beneficial effect of the present invention:
One, pharmacodynamic experiment of the present invention:
(1) experiment medicine:
Medicine of the present invention is pressed embodiment 1 preparation, and content is 2g crude drug/ml;
Cyclophosphamide (CTX), Hualian Pharmaceutical Co., Ltd., Shanghai.
The medicine preparation: the sodium carboxymethyl cellulose (CMC) that faces with preceding usefulness 0.5% is made into desired concn.
(2) laboratory animal:
The ICR mice, 18-22g, animal housing of China Medicine University provides;
Nude mouse, 18-22g, the Shanghai Experimental Animal Center provides.
(3) tumor strain source:
Transplanted tumor sarcoma 180 (S
180), the strain of hepatocarcinoma nude type (Heps) tumor provides by Jiangsu Province's tumour medicine institute;
People's adenocarcinoma of stomach BGC-823 cell is provided by Chinese Academy of Sciences's Shanghai cell.
(4) experimental technique and result
1, medicine of the present invention is to mice-transplanted tumor S
180Inhibitory action
Get 50 of mices, press transplanted tumor organon inoculation S
180Inoculate back 24 hours and claim Mus heavy, and be divided into 5 groups at random, be blank group (0.5%CMC solution, 0.5ml/20g), CTX group (CTX30mg/kg), the high, medium and low dosage group of medicine of the present invention (give medicine 22g crude drug/kg of the present invention, 11g crude drug/kg, 5.5g crude drug/kg) respectively, every group 10, male and female half and half.In inoculation po administration after 24 hours, once a day, altogether administration is 8 times, weighs in the 1st day after the drug withdrawal, puts to death mice and also separates the tumor piece, and is steady and carry out statistical procedures (t check), and experimental result sees Table 1.
Table 1 medicine of the present invention is to mice-transplanted tumor S
180Inhibitory action (x ± SD, n=10)
| Group | Dosage (mg/kg) | Mice body weight (g) | Tumor weight (g) | Tumour inhibiting rate (%) | |
| Before the administration | After the administration | ||||
| The blank group | - | ?19.0±0.92 | ?22.5±1.69 | ?1.77±0.75 | |
| Medicine group of the present invention | 5.5g/kg | ?19.0±1.49 | ?22.5±2.99 | ?1.36±0.52 | ?23.2 |
| 11g/kg | ?19.0±1.37 | ?22.6±3.04 | ?1.21±0.28 * | ?31.6 | |
| ?22g/kg | ?19.1±1.50 | ?22.5±2.32 | 1.06±0.58 * | 40.1 | |
| The CTX group | ?20 | ?19.0±1.20 | ?18.3±1.20 ** | 0.97±0.14 ** | 45.2 |
Compare with the blank group,
*P＜0.05
*P＜0.01
The result shows, compares with the blank group, and medicine height of the present invention, middle dosage group and CTX group suppress mice S all very significantly
180Tumor growth effect (P＜0.01), but CTX group has and suppresses the weight of mice effect significantly, and medicine of the present invention does not have obvious influence to weight of mice.
2, medicine of the present invention is to the inhibitory action of mice-transplanted tumor Heps
Get 50 of mices, press transplanted tumor organon inoculation Heps, inoculate back 24 hours and claim Mus heavy, and be divided into 5 groups at random, be blank group (0.5%CMC solution, 0.5ml/20g), CTX group (CTX 30mg/kg), the high, medium and low dosage group of medicine of the present invention (give medicine 22g crude drug/kg of the present invention, 11g crude drug/kg, 5.5g crude drug/kg) respectively, 10 every group, male and female half and half.In inoculation po administration after 24 hours, once a day, altogether administration is 9 times, weighs in the 1st day after the drug withdrawal, puts to death mice and also separates the tumor piece, and is steady and carry out statistical procedures (t check), and experimental result sees Table 2.
Table 2 medicine of the present invention to the inhibitory action of mice-transplanted tumor Heps (x ± SD, n=10)
| Group | Dosage (mg/kg) | Mice body weight (g) | Tumor weight (g) | Tumour inhibiting rate (%) | |
| Before the administration | After the administration | ||||
| The blank group | - | ?19.0±1.28 | ?22.9±2.47 | ?1.58±0.29 | |
| Medicine group of the present invention | 5.5g/kg | ?19.0±1.02 | ?22.7±2.23 | ?1.37±0.53 | 13.3 |
| 11g/kg | ?18.9±1.61 | ?22.6±2.70 | ?1.00±0.44 ** | 36.7 | |
| 22g/kg | ?19.1±1.17 | ?22.6±2.61 | ?0.85±0.34 ** | 46.2 | |
| The CTX group | 20 | ?19.0±1.10 | ?18.4±1.34 ** | ?0.73±0.19 ** | 53.8 |
Compare with the blank group,
*P＜0.05
*P＜0.01
The result shows, compare with the blank group, medicine height of the present invention, middle dosage group and CTX group suppress the tumor growth effect (P＜0.01) of mice Heps all very significantly, but CTX organizes to have and suppresses the weight of mice effect significantly, and medicine of the present invention does not have obvious influence to weight of mice.
3, medicine of the present invention is to the inhibitory action of people's gastric cancer BGC-823 Nude Mice
The tumor tissue of getting the growth animated period cuts into 1.5mm
3About, under aseptic condition, it is subcutaneous to be inoculated in nude mouse right side axillary fossa.Nude Mice treats that with vernier caliper measurement transplanted tumor diameter tumor growth is to 100-300mm
3After animal is divided into 5 groups at random, be that each 6 of 12 of blank groups (giving the equal-volume normal saline), CTX groups 6 (CTX30mg/kg), the high, medium and low dosage group of medicine of the present invention (give medicine 22g crude drug/kg of the present invention, 11g crude drug/kg, 5.5g crude drug/kg) respectively, blank group and CTX group adopt the administration of iv mode, and medicine group of the present invention adopts the administration of po mode.Use the method for measuring the tumor footpath, dynamic observe tested animal antineoplastic effect.The measurement number of times of diameter of tumor is that each the measurement also need claim Mus heavy simultaneously 3 times weekly.Medicine group oral administration of the present invention 6 times weekly, CTX organizes weekly intravenously administrable 2 times.Gross tumor volume (TV) computing formula is: TV=1/2 * a * b
2, wherein a, b represent length and width respectively.Calculate relative tumour volume (RTV) according to measurement result, formula is: RTV=V
t/ V
0, V wherein
0(d during for minute cage administration
0) measurement gained gross tumor volume, V
tGross tumor volume when measuring each time.The evaluation index of anti-tumor activity is relative tumor proliferation rate T/C (%), and formula is: T/C (%)=T
RTV/ C
RTV* 100, T wherein
RTVBe treatment group RTV, C
RTVBe blank group RTV.The results are shown in Table 3.
Table 3 medicine of the present invention is to the inhibitory action of people's gastric cancer BGC-823 Nude Mice
| Group | Dosage | Body weight | TV(x±SD) | RTV (x±SD) | T/C (％) | The P value | ||
| (mg/kg) | Beginning | At last | ????d 0 | ??d 10 | ||||
| The blank group | 20ml/ only | 19.4± 1.3 | 21.9± 1.4 | 104± 43 | ?1347± ?456 | ?12.4± ?3.5 | ||
| The CTX group | 30 | 20.2± 0.9 | 20.2± 0.9 | 101± 32 | ?633± ?340 | ?5.7± ?1.1 | ?46.0 | ＜0.01 |
| Medicine group of the present invention | 22g/kg | 19.0± 0.9 | 19.0± 0.9 | 109± 47 | ?704± ?101 | ?6.5± ?0.5 | ?52.4 | ＜0.01 |
| 11g/kg | 19.4± 1.8 | 19.4± 1.8 | 94±42 | ?899± ?629 | ?9.1± ?4.6 | ?73.4 | ＞0.05 | |
| 5.5g/kg | 18.9± 0.7 | 18.9± 0.7 | 105± 35 | ?1065± ?359 | ?10.1± ?23 | ?81.5 | ＞0.05 | |
The result shows, compare with the blank group, medicine high dose group of the present invention and CTX group suppress the growth (P＜0.01) of people's gastric cancer BGC-823 Nude Mice all very significantly, but CTX organizes to have and suppresses the weight of mice effect significantly, and medicine of the present invention does not have obvious influence to weight of mice.
Two, toxicological experiment of the present invention
1, acute toxicity test in mice
Get 20 of mices, male and female half and half, on an empty stomach after 12 hours, gastric infusion 1 time, dosage is maximum drug level 2g crude drug/ml, the maximum long-pending 0.8ml/20g of body of stomach that irritates after the administration, observes mice activity and death condition every day, observed 7 days continuously, after administration, claimed the mice body weight on the 8th day, and calculate the body weight gain rate, the results are shown in Table.
Table 4 medicine of the present invention is to the influence of mice body weight (x ± SD)
| Sex | Mus number (only) | Body weight | Body weight gain rate (%) | |
| Before the administration | After the drug withdrawal | |||
| Male | 10 | ?19.4±1.26 | ?25.4±0.98 | ?30.9 |
| Female | 10 | ?19.2±1.17 | ?24.3±0.78 | ?26.6 |
The result shows that dead and any toxic and side effects do not appear in mice, can't try to achieve mice LD
50Value.The mice body weight all increases to some extent, male mice body weight gain rate is 30.9%, female mice body weight gain rate is 26.6%, the maximum drug resistance amount of the present invention's gastric infusion on the one is 80g crude drug/kg, (the clinical consumption of being grown up is a 0.8333g crude drug/kg), show that clinical practice is safe to be equivalent to be grown up 96 times of consumption every day.
Three, preparation technology's characteristics of the present invention are for adopting superfine communication technique, Pseudobulbus Bletillae (Rhizoma Bletillae) medical material directly is used as medicine with micropowder, can help the absorption of medicine, reduce yield of extract, increase preparation stability, and specific surface area increases after the micronizing, wettability strengthens, and more effectively absorbs the moisture in other medicinal substances extracts, has reduced dose, and effectively keep the activity of medical material effective ingredient, strengthen its curative effect.For Herba Hedyotidis Diffusae and Herba Solani Lyrati, adopt its liposoluble constituent of ethanol extraction, its water soluble ingredient of water extraction is to guarantee that its effective ingredient obtains ground and fully extracts.
The specific embodiment
The invention will be further elaborated by the following examples.
Raw medicinal material is pressed the calculating of 1000g/ part among the embodiment.
Embodiment 1
Prescription: 2 parts of Herba Hedyotidis Diffusaes, 2 parts of the Pseudobulbus Bletillae (Rhizoma Bletillae)s, 8 parts of Herba Solani Lyratis.
Preparation technology: get the Pseudobulbus Bletillae (Rhizoma Bletillae) by above-mentioned prescription and adopt superfine communication technique to be ground into Pseudobulbus Bletillae (Rhizoma Bletillae) micropowder (20 μ m), standby; Get Herba Hedyotidis Diffusae and Herba Solani Lyrati, add 10 times of amount 70% alcohol reflux 2 times, each 2 hours, backflow left standstill, and filtered, and reclaimed ethanol, and filtrate concentrates, and gets clear paste I; Medicinal residues decoct 2 times with 8 times of water gagings, each 2 hours, discard medicinal residues, get that decoction liquor leaves standstill, filtration, filtrate concentrate, clear paste II; Pseudobulbus Bletillae (Rhizoma Bletillae) micropowder, clear paste I, clear paste II are mixed, add suitable adjuvant, granulate by the granule common process, drying, granular preparation is promptly made in packing.
Embodiment 2
Prescription: 16 parts of Herba Hedyotidis Diffusaes, 16 parts of the Pseudobulbus Bletillae (Rhizoma Bletillae)s, 5 parts of Herba Solani Lyratis.
Preparation technology: get the Pseudobulbus Bletillae (Rhizoma Bletillae) by above-mentioned prescription and adopt superfine communication technique to be ground into Pseudobulbus Bletillae (Rhizoma Bletillae) micropowder (10 μ m), standby; Get Herba Hedyotidis Diffusae and Herba Solani Lyrati, add 6 times of amount 95% alcohol reflux 3 times, each 3 hours, backflow left standstill, and filtered, and reclaimed ethanol, and filtrate concentrates, and gets clear paste I; 10 times of medicinal residues waters amount decocts 3 times, each 1 hour, discard medicinal residues, get that decoction liquor leaves standstill, filtration, filtrate concentrate, clear paste II; Pseudobulbus Bletillae (Rhizoma Bletillae) micropowder, clear paste I, clear paste II are mixed, add suitable adjuvant, mix by the tablet common process, tabletting, tablet is promptly made in packing.
Embodiment 3
Prescription: 12 parts of Herba Hedyotidis Diffusaes, 12 parts of the Pseudobulbus Bletillae (Rhizoma Bletillae)s, 2 parts of Herba Solani Lyratis.
Preparation technology: get the Pseudobulbus Bletillae (Rhizoma Bletillae) by above-mentioned prescription and adopt superfine communication technique to be ground into Pseudobulbus Bletillae (Rhizoma Bletillae) micropowder (15 μ m), standby; Get Herba Hedyotidis Diffusae and Herba Solani Lyrati, add 8 times of amount 90% alcohol reflux 2 times, each 1.5 hours, backflow left standstill, and filtered, and reclaimed ethanol, and filtrate concentrates, and gets clear paste I; Medicinal residues decoct 3 times with 10 times of water gagings, each 2 hours, discard medicinal residues, get that decoction liquor leaves standstill, filtration, filtrate concentrate, clear paste II; Pseudobulbus Bletillae (Rhizoma Bletillae) micropowder, clear paste I, clear paste II are mixed, add suitable adjuvant, make granule by the capsule common process.
Embodiment 4
Prescription: 2 parts of Herba Hedyotidis Diffusaes, 2 parts of the Pseudobulbus Bletillae (Rhizoma Bletillae)s, 8 parts of Herba Solani Lyratis.
Preparation technology: get the Pseudobulbus Bletillae (Rhizoma Bletillae) by above-mentioned prescription and adopt superfine communication technique to be ground into micropowder (8 μ m), standby; Get Herba Hedyotidis Diffusae and Herba Solani Lyrati, add 9 times of amount 70% alcohol reflux 2 times, each 2 hours, backflow left standstill, and filtered, and reclaimed ethanol, and filtrate concentrates, and gets clear paste I; Medicinal residues decoct 2 times with 7 times of water gagings, each 2 hours, discard medicinal residues, get that decoction liquor leaves standstill, filtration, filtrate concentrate, clear paste II; Pseudobulbus Bletillae (Rhizoma Bletillae) micropowder, clear paste I, clear paste II are mixed, add suitable adjuvant, granulate by the granule common process, drying, capsule preparations is promptly made in packing.
Claims (5)
1, a kind of Chinese medicine for the treatment of gastric cancer is characterized in that, it is formulated by following bulk drugs:
Herba Hedyotidis Diffusae 2-16 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 2-16 part, Herba Solani Lyrati 1-8 part.
2, the Chinese medicine of treatment gastric cancer according to claim 1 is characterized in that, its dosage form is the dosage form that allows on any pharmaceutics.
3, the Chinese medicine of treatment gastric cancer according to claim 2 is characterized in that, its medicament is pill, tablet, powder, granule, capsule, drop pill, syrup, medicated wine, oral solutions, injection.
4, the preparation technology of the Chinese medicine of treatment gastric cancer as claimed in claim 1 is characterized in that, its preparation process is as follows:
A. get the Pseudobulbus Bletillae (Rhizoma Bletillae) by above-mentioned prescription and adopt superfine communication technique to be ground into micropowder, standby;
B. get Herba Hedyotidis Diffusae and Herba Solani Lyrati, 6-10 times of 70-95% alcohol reflux 2-3 time, each 1-3 hour, backflow left standstill, and filtered, and reclaimed ethanol, filtrate concentrates, clear paste I; Medicinal residues boil 2-3 time with 6-10 times of decocting, each 1-3 hour, discard medicinal residues, get that decoction liquor leaves standstill, filtration, filtrate concentrate, clear paste II;
C. Pseudobulbus Bletillae (Rhizoma Bletillae) micropowder, clear paste I, clear paste II are mixed, technology adds suitable adjuvant and makes required dosage form routinely.
5, preparation technology according to claim 4 is characterized in that the average diameter≤20 μ m of Pseudobulbus Bletillae (Rhizoma Bletillae) micropowder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510038885 CN1291743C (en) | 2005-04-15 | 2005-04-15 | Traditional Chinese medicine for treating stomach cancer and its preparation technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510038885 CN1291743C (en) | 2005-04-15 | 2005-04-15 | Traditional Chinese medicine for treating stomach cancer and its preparation technology |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686281A true CN1686281A (en) | 2005-10-26 |
| CN1291743C CN1291743C (en) | 2006-12-27 |
Family
ID=35304323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510038885 Expired - Fee Related CN1291743C (en) | 2005-04-15 | 2005-04-15 | Traditional Chinese medicine for treating stomach cancer and its preparation technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1291743C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105797003A (en) * | 2016-04-20 | 2016-07-27 | 三株福尔制药有限公司 | Probiotics fermentation traditional Chinese medicine compound composition for treating colorectal cancer and preparation method and application thereof |
| CN106334093A (en) * | 2016-10-17 | 2017-01-18 | 南宁多灵生物科技有限公司 | Traditional Chinese medicine composition for treating stomach cancer |
-
2005
- 2005-04-15 CN CN 200510038885 patent/CN1291743C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105797003A (en) * | 2016-04-20 | 2016-07-27 | 三株福尔制药有限公司 | Probiotics fermentation traditional Chinese medicine compound composition for treating colorectal cancer and preparation method and application thereof |
| CN105797003B (en) * | 2016-04-20 | 2019-08-06 | 三株福尔制药有限公司 | A kind of probiotics fermention Traditional Chinese medicine compound composition and its preparation method and application for treating colon cancer |
| CN106334093A (en) * | 2016-10-17 | 2017-01-18 | 南宁多灵生物科技有限公司 | Traditional Chinese medicine composition for treating stomach cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1291743C (en) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103099959B (en) | Traditional Chinese medicine preparation for treating ulcerative colitis and preparation method thereof | |
| CN1899379A (en) | External plaster for treating child cold diarrhea and preparing method | |
| CN102697903A (en) | Medicine for treating herpes zoster | |
| CN102772781A (en) | Traditional Chinese medicine preparation for treating chronic colitis and preparation method thereof | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN1899455A (en) | External use plaster for treating child heat diarrhea and preparing method | |
| CN111375035B (en) | Preparation and application of enteric-coated preparation for treating cervical spondylosis | |
| CN1291743C (en) | Traditional Chinese medicine for treating stomach cancer and its preparation technology | |
| CN101564464B (en) | Chinese medicament for adjusting organism immunity of tumor patients | |
| CN101474388B (en) | Improved prescription of Xianchan tablet medicament and preparation method thereof | |
| CN104324261A (en) | Pharmaceutical composition for treating high blood sugar and preparation method of pharmaceutical composition | |
| CN101045116B (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN1943632A (en) | A kind of medicine for treating infant cold and its preparing method | |
| CN1537559A (en) | Traditional Chinese medicine for treating AIDS | |
| CN1110161A (en) | Traditional Chinese Medicine preparation for mainly curing myopia | |
| CN100339093C (en) | Compound medicine for treating coronary heart disease and angina pectoris and its preparing process | |
| CN1544078A (en) | Chinese patent medicine for treating leukopenia due to tumor treating radiotherapy and chemotherapy | |
| CN1064249C (en) | Traditional Chinese medicine for indication nearsight | |
| CN100335111C (en) | Medicine for rheumatism and its preparation | |
| CN104840746B (en) | A kind of Chinese medicine composition with anti-lung cancer activity and its preparation method and application | |
| CN1304043C (en) | Longhedan pills and their preparation | |
| CN104825980A (en) | Traditional Chinese medicine preparation for treating diarrhea | |
| CN1504231A (en) | Medicine for tumour | |
| CN104436021A (en) | Arctium-containing traditional Chinese medicine composition for treating diabetes mellitus | |
| CN104258302A (en) | Traditional Chinese medicine for treating chronic idiopathic thrombocytopenic purpura due to fire excess from yin deficiency and preparation method of traditional Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061227 |